SRZN [NASD]
Surrozen, Inc.
Index- P/E- EPS (ttm)-4.24 Insider Own6.88% Shs Outstand34.86M Perf Week-2.26%
Market Cap99.74M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float34.61M Perf Month-13.67%
Income- PEG- EPS next Q-0.47 Inst Own71.70% Short Float0.46% Perf Quarter-2.26%
Sales- P/S- EPS this Y-137.00% Inst Trans-5.13% Short Ratio2.83 Perf Half Y-71.60%
Book/sh2.94 P/B0.88 EPS next Y25.70% ROA- Target Price16.33 Perf Year-73.71%
Cash/sh2.40 P/C1.08 EPS next 5Y29.90% ROE- 52W Range1.98 - 14.00 Perf YTD-59.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-81.50% Beta-
Dividend %- Quick Ratio11.80 Sales past 5Y- Gross Margin- 52W Low30.81% ATR0.23
Employees83 Current Ratio11.80 Sales Q/Q- Oper. Margin- RSI (14)47.90 Volatility6.15% 8.46%
OptionableNo Debt/Eq0.00 EPS Q/Q26.30% Profit Margin- Rel Volume0.01 Prev Close2.54
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume56.35K Price2.59
Recom1.00 SMA200.49% SMA50-10.19% SMA200-54.18% Volume445 Change1.78%
Oct-11-21Initiated BofA Securities Buy $11
Sep-15-21Initiated Guggenheim Buy $20
Sep-07-21Initiated Stifel Buy $19
May-24-22 08:00AM  
May-18-22 08:00AM  
May-16-22 08:00AM  
May-11-22 08:00AM  
May-05-22 08:00AM  
May-02-22 08:00AM  
Mar-24-22 08:00AM  
Jan-20-22 09:00AM  
Jan-10-22 08:00AM  
Jan-05-22 08:00AM  
Nov-15-21 04:00PM  
08:00AM  
08:00AM  
Nov-11-21 10:51AM  
Nov-05-21 08:00AM  
Oct-05-21 04:30PM  
Sep-23-21 08:30AM  
Aug-11-21 05:30PM  
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.